LY4395089

DRUG3 trials

Sponsors

Eli Lilly and Company

Conditions

Colitis, UlcerativeCrohn DiseaseHealthy

Phase 1

A Study of the Effects of Itraconazole on LY4395089 in Healthy Participants

CompletedNCT07592572

Eli Lilly and CompanyHealthy

Start: 2026-05-20End: 2026-07-08Updated: 2026-08-25

Phase 2

A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease

RecruitingNCT07483073

Eli Lilly and CompanyColitis, Ulcerative, Crohn Disease

Start: 2026-05-04End: 2028-03-01Target: 60Updated: 2026-09-08

A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease

RecruitingNCT07483099

Eli Lilly and CompanyCrohn Disease

Start: 2026-05-04End: 2028-03-01Target: 60Updated: 2026-09-08